Literature DB >> 19061859

Surface plasmon resonance characterization of specific binding of polyglutamine aggregation inhibitors to the expanded polyglutamine stretch.

Yuma Okamoto1, Yoshitaka Nagai, Nobuhiro Fujikake, H Akiko Popiel, Tohru Yoshioka, Tatsushi Toda, Takashi Inui.   

Abstract

Proteins with an abnormally expanded polyglutamine (polyQ) stretch are prone to change their conformations, leading to their aggregation, and cause inherited neurodegenerative diseases called the polyQ diseases. Although screening for polyQ aggregation inhibitors has been extensively performed, many common false-positive hits have been identified so far. In this study, we employed surface plasmon resonance (SPR) to characterize the binding specificities and affinities of polyQ aggregation inhibitors to the expanded polyQ stretch. SPR successfully detected specific binding of polyQ binding peptide 1 (QBP1) to the expanded polyQ stretch (K(d)=5.7 microM), and non-specific binding of Congo red to polyQ proteins independent of their polyQ-length. Binding affinities of polyQ aggregation inhibitors to the expanded polyQ stretch were correlated with their inhibitory effects on polyQ aggregation. We therefore conclude that SPR is a useful technique for screening for specific polyQ aggregation inhibitors as promising therapeutic candidates for the currently untreatable polyQ diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19061859     DOI: 10.1016/j.bbrc.2008.11.094

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.

Authors:  H Akiko Popiel; Toshihide Takeuchi; James R Burke; Warren J Strittmatter; Tatsushi Toda; Keiji Wada; Yoshitaka Nagai
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

2.  The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.

Authors:  H Akiko Popiel; James R Burke; Warren J Strittmatter; Shinya Oishi; Nobutaka Fujii; Toshihide Takeuchi; Tatsushi Toda; Keiji Wada; Yoshitaka Nagai
Journal:  J Amino Acids       Date:  2011-06-30

Review 3.  Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases.

Authors:  Eiko N Minakawa; Yoshitaka Nagai
Journal:  Front Neurosci       Date:  2021-02-12       Impact factor: 4.677

4.  Identification of a novel site of interaction between ataxin-3 and the amyloid aggregation inhibitor polyglutamine binding peptide 1.

Authors:  Patrick D Knight; Theodoros K Karamanos; Sheena E Radford; Alison E Ashcroft
Journal:  Eur J Mass Spectrom (Chichester)       Date:  2017-08-29       Impact factor: 1.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.